Friedman Center for Nutrition & Inflammation
Found 150 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2021
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V, Bram Y et al..  2021.  Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance.. medRxiv.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V, Bram Y et al..  2021.  Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance.. medRxiv.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(12):2484.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(12):2484.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(11):2174-2188.e5.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(11):2174-2188.e5.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(12):2484.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(11):2174-2188.e5.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(11):2174-2188.e5.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(12):2484.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(12):2484.
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V et al..  2021.  Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.. Cell Metab. 33(11):2174-2188.e5.
Teng F, Tachó-Piñot R, Sung B, Farber DL, Worgall S, Hammad H, Lambrecht BN, Hepworth MR, Sonnenberg GF.  2021.  ILC3s control airway inflammation by limiting T cell responses to allergens and microbes.. Cell Rep. 37(8):110051.
Teng F, Tachó-Piñot R, Sung B, Farber DL, Worgall S, Hammad H, Lambrecht BN, Hepworth MR, Sonnenberg GF.  2021.  ILC3s control airway inflammation by limiting T cell responses to allergens and microbes.. Cell Rep. 37(8):110051.
Charilaou P, Tricarico C, Battat R, Scherl EJ, Longman RS, Lukin DJ.  2021.  Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination.. Clin Gastroenterol Hepatol.
Charbord J, Ren L, Sharma RB, Johansson A, Ågren R, Chu L, Tworus D, Schulz N, Charbord P, Stewart AF et al..  2021.  In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR.. Nat Metab. 3(5):682-700.
Charbord J, Ren L, Sharma RB, Johansson A, Ågren R, Chu L, Tworus D, Schulz N, Charbord P, Stewart AF et al..  2021.  In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR.. Nat Metab. 3(5):682-700.
Charbord J, Ren L, Sharma RB, Johansson A, Ågren R, Chu L, Tworus D, Schulz N, Charbord P, Stewart AF et al..  2021.  In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR.. Nat Metab. 3(5):682-700.
Tchang BG, Askin G, Sahagun A, Hwang J, Huang H, Curanaj FAMendelso, Seley JJ, Safford MM, Alonso LC, Aronne LJ et al..  2021.  The Independent Risk of Obesity and Diabetes and Their Interaction in COVID-19: A Retrospective Cohort Study.. Obesity (Silver Spring). 29(6):971-975.
Tchang BG, Askin G, Sahagun A, Hwang J, Huang H, Curanaj FAMendelso, Seley JJ, Safford MM, Alonso LC, Aronne LJ et al..  2021.  The Independent Risk of Obesity and Diabetes and Their Interaction in COVID-19: A Retrospective Cohort Study.. Obesity (Silver Spring). 29(6):971-975.
Tchang BG, Askin G, Sahagun A, Hwang J, Huang H, Curanaj FAMendelso, Seley JJ, Safford MM, Alonso LC, Aronne LJ et al..  2021.  The Independent Risk of Obesity and Diabetes and Their Interaction in COVID-19: A Retrospective Cohort Study.. Obesity (Silver Spring). 29(6):971-975.
Tchang BG, Askin G, Sahagun A, Hwang J, Huang H, Curanaj FAMendelso, Seley JJ, Safford MM, Alonso LC, Aronne LJ et al..  2021.  The Independent Risk of Obesity and Diabetes and Their Interaction in COVID-19: A Retrospective Cohort Study.. Obesity (Silver Spring). 29(6):971-975.
Winkler A, Sun W, De S, Jiao A, M Sharif N, Symanowicz PT, Athale S, Shin JH, Wang J, Jacobson BA et al..  2021.  The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.. Arthritis Rheumatol. 73(12):2206-2218.
Winkler A, Sun W, De S, Jiao A, M Sharif N, Symanowicz PT, Athale S, Shin JH, Wang J, Jacobson BA et al..  2021.  The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.. Arthritis Rheumatol. 73(12):2206-2218.
Winkler A, Sun W, De S, Jiao A, M Sharif N, Symanowicz PT, Athale S, Shin JH, Wang J, Jacobson BA et al..  2021.  The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.. Arthritis Rheumatol. 73(12):2206-2218.